Emulsion and liposome-based adjuvanted R21 vaccine formulations mediate protection against malaria through distinct immune mechanisms

Adjuvanted protein vaccines offer high efficacy, yet most potent adjuvants remain proprietary. Several adjuvant compounds are being developed by the Vaccine Formulation Institute in Switzerland for global open access clinical use. In the context of the R21 malaria vaccine, in a mouse challenge model...

Descripción completa

Detalles Bibliográficos
Autores principales: Reinke, Sören, Pantazi, Eirini, Chappell, Gabrielle R., Sanchez-Martinez, Alexandra, Guyon, Romain, Fergusson, Joannah R., Salman, Ahmed M., Aktar, Anjum, Mukhopadhyay, Ekta, Ventura, Roland A., Auderset, Floriane, Dubois, Patrice M., Collin, Nicolas, Hill, Adrian V.S., Bezbradica, Jelena S., Milicic, Anita
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10694591/
https://www.ncbi.nlm.nih.gov/pubmed/37913775
http://dx.doi.org/10.1016/j.xcrm.2023.101245

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10694591/
https://www.ncbi.nlm.nih.gov/pubmed/37913775
http://dx.doi.org/10.1016/j.xcrm.2023.101245

Ejemplares similares